The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
EMED · Healthcare · Shallow moat
Doesn't clear the bar
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
| Measure | EMED | MTEX | VCYT | SUPN |
|---|---|---|---|---|
| Moat Score (0–100) | 59 (highest) | 59 (highest) | 59 (highest) | 58 |
| Methodology version | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 |
| Business trend | 63 | 19 | 75 (highest) | 61 |
| Pricing power | 99 | 100 (highest) | 96 | 98 |
| Returns on capital | — | 84 (highest) | 0 | 78 |
| Balance-sheet safety | 28 | 28 | 100 (highest) | 55 |
| Capital discipline | 44 | 64 (highest) | 24 | 0 |
| Price vs. high estimate | No price data | No price data | No price data | 186% above high estimate |
| Market cap | $46329 | $8.1M | $4.5B | $2.7B |
| Moat tier | Shallow moat | Shallow moat | Shallow moat | Shallow moat |
| Filings as of | FY2023 | FY2025 | FY2025 | FY2025 |